Request Trial
shutterstock_607718810_vchal
vchal / Shutterstock.com
14 November 2019EuropeRory O'Neill

Merck and Evotec strike CRISPR licensing deal

Merck has agreed to license its CRISPR gene-editing technology to German biotech company Evotec.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
UPC upholds injunction in Invisalign maker’s software dispute with rival
9 July 2026   China-headquartered Angelalign failed to convince UPC appellate judges to overturn a ban that affects its ability to offer orthodontic planning software in Europe with certain functionality.
Europe
BioNTech and Pfizer secure big European win over mRNA patent
8 July 2026   UPC judges revoke a patent asserted against the companies over their Comirnaty COVID-19 vaccine, in a ruling that clarified the court’s key principles on exclusive licences, novelty and inventive step.
Europe
UPC revives patent, but timing sinks Guardant’s appeal
6 July 2026   The Unified Patent Court delivers a mixed ruling in a dispute over liquid biopsy technology, overturning a finding that a patent was likely invalid while refusing to grant interim relief because of the patent owner’s delay.


Editor's picks

What’s at stake in Australia’s biggest pharma patent appeal in years?
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026

Editor's picks

Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026

More features

Exelixis opens two-front patent dispute over Cabometyx copies
UPC upholds injunction in Invisalign maker’s software dispute with rival
BioNTech and Pfizer secure big European win over mRNA patent
Pillsbury nabs ‘veteran’ IP litigator and trial lawyer from Goodwin
Influential Women in IP 2026: Who made the list?
WilmerHale trade secrets expert moves to new firm
UPC revives patent, but timing sinks Guardant’s appeal
China’s medtech shake-up forces rethink on pricing, IP and innovation